摘要
目的探讨来氟米特联合缬沙坦治疗糖尿病肾病蛋白尿的疗效及安全性。方法纳入该院100例确诊为糖尿病肾病的患者,24 h尿蛋白定量≥1 g/d,随机抽签分为两组,各50例。对照组50例应用常规剂量缬沙坦治疗糖尿病肾病,观察组50例在应用常规剂量缬沙坦的基础上,给予来氟米特联合治疗糖尿病肾病。比较两组患者治疗后3个月疗效,24 h尿蛋白定量、尿素氮、肌酐、超敏C反应蛋白及不良反应发生情况。结果观察组总有效率明显高于对照组(P<0.05)。观察组24 h尿蛋白定量、尿素氮、肌酐、超敏C反应蛋白显著低于对照组(P<0.05)。两组胃肠道反应、皮疹、ALT升高、WBC下降的总发生率差异无统计学意义(P>0.05)。结论来氟米特联合缬沙坦较单独使用缬沙坦治疗能够更好的治疗糖尿病肾病蛋白尿,且对患者的不良反应较小,因此临床使用来氟米特来氟米特联合缬沙坦治疗糖尿病肾病蛋白尿是一种安全、可行的方法。
Objective To study the curative effect and safety of leflunomide combined with valsartan in treatment of diabet- ic renal proteinuria. Methods 100 cases of patients with diabetic nephropathy in our hospital whose 24 h urine protein quantitation ≥ 1 g/d were selected and randomly divided into two groups with 50 cases in each, the control group adopted the routine-dose valsartan, while the observation group adopted the leflunomide on the basis of the control group, and the curative effect in 3 months after treatment, 24 h urine protein quantitation, urea nitrogen, creatinine and hs-CRP an occur- rence of adverse reactions were compared between the two groups. Results The total effective rate in the observation group was obviously higher than that in the control group （P〈0.05）, and the 24 h urine protein quantitation, urea nitrogen, creati- nine and hs-CRP an occurrence of adverse reactions in the observation group were obviously lower than those in the control group（P〈0.05 ）, and there was no obvious difference in the total incidence rate of gastrointestinal reaction, rash, ALT eleva- tion and WBC decrease between the two groups（P〉0.05）. Conclusion Leflunomide combined with valsartan in treatment of diabetic renal proteinuria can better treat the diabetic renal proteinuria compared with the single use of valsartan with fewer adverse reactions, therefore, it is a safe and feasible method in clinic.
出处
《糖尿病新世界》
2017年第5期17-19,共3页
Diabetes New World Magazine
关键词
来氟米特
糖尿病肾病蛋白尿
疗效
安全性
Leflunomide
Diabetic renal proteinuria
Curative effect
Safety
